You have accessJournal of UrologyCME1 Apr 2023MP54-03 THE EFFECT OF DUAL ELIGIBILITY ON ACCESS TO CARE IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER Kassem Faraj, Rodney Dunn, Brent Hollenbeck, and Lindsey Herrel Kassem FarajKassem Faraj More articles by this author , Rodney DunnRodney Dunn More articles by this author , Brent HollenbeckBrent Hollenbeck More articles by this author , and Lindsey HerrelLindsey Herrel More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003307.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Dual eligible beneficiaries are a particularly vulnerable population, as they qualify for Medicare due to age and Medicaid due to low income. Though some dual eligible beneficiaries have access to additional social services, such as transportation coverage, others do not qualify for these services (i.e. partial dual eligibility). This heterogeneity in support services may impact access to treatment for dual eligible men with newly diagnosed prostate cancer, a condition that necessitates timely, repeated interactions with the healthcare system. METHODS: We performed a cohort study of Medicare beneficiaries who were diagnosed with prostate cancer between 2015 and 2019. Beneficiaries were required to have 12-months of eligibility before and after diagnosis date. We compared pre-diagnosis testing, post-diagnosis testing, and primary prostate cancer treatment between beneficiaries who have full dual-eligibility (full duals, “F”), partial dual-eligibility (partial duals, “P”) and those who are not dual-eligible (non-duals, “N”). RESULTS: In 138,785 men with newly diagnosed prostate cancer, 4,611 (3.3%) were full duals and 2,031 (1.5%) were partial duals. Full and partial duals (Figure 1) were more often of Black race than non-duals (p<0.001). Partial duals were less likely to have a PSA (p<0.001) or multiparametric MRI (p<0.001) prior to diagnosis, compared to both duals and non-duals. After diagnosis, full and partial duals less commonly underwent multiparametric MRI (F-17%, P-15%, N-24%, p<0.001) and more commonly underwent bone scan (F-43%, P-42%, N-33%, p<0.001) compared to non-duals. Regarding treatment (Figure 1), full and partial duals less commonly underwent surgery (F-12%, P-13%, N-20%) and more commonly received androgen deprivation therapy as a primary treatment (F-16%, P-13%, N-7%) compared to non-duals (p<0.001). CONCLUSIONS: Our findings demonstrate disparities in access for dual-eligible beneficiaries before and after a new prostate cancer diagnosis. A more advanced stage at diagnosis may be reflected by the higher rates of bone scan testing and treatment with primary androgen deprivation therapy in the duals. A deeper understanding of barriers in access to prostate cancer screening and treatment is needed for this particularly vulnerable population. Source of Funding: This study is supported by funding from the National Cancer Institute Advanced Training in Urologic Oncology T32 Grant No T32CA180984 (Faraj) and by funding from the Prostate Cancer Foundation-Pfizer Health Equity Grant No K08CA237638 (Herrel) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e754 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kassem Faraj More articles by this author Rodney Dunn More articles by this author Brent Hollenbeck More articles by this author Lindsey Herrel More articles by this author Expand All Advertisement PDF downloadLoading ...
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Access
Sep 28, 2024
Minhong Huang + 8
